Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 8—August 2024
Research

Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance

C. Finn McQuaidComments to Author , Theresa S. Ryckman, Nicolas A. Menzies, Richard G. White, Ted Cohen, and Emily A. Kendall
Author affiliations: London School of Hygiene and Tropical Medicine, London, UK (C.F. McQuaid, R.G. White); Johns Hopkins University School of Medicine, Baltimore, Maryland, USA (T.S. Ryckman, E.A. Kendall); Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (N.A. Menzies); Yale School of Public Health, New Haven, Connecticut, USA (T. Cohen)

Main Article

Figure 4

Sensitivity analysis for TB treatment regimen comparison after use in multiple patient cohorts in study of potential of pan-TB treatment to drive emergence of novel resistance. Comparison shows an outcome of proportion of patients durably cured in the 10th cohort when using either the pan-TB or the SoC approach for 10 cohorts. A) Univariate sensitivity analysis, sampling parameter sets with 1 parameter fixed at an extreme of its 95% CI, where blue circles indicate high parameter values and red circles low parameter values. B) Multivariate sensitivity analysis varying 2 resistance-related parameters simultaneously, where red indicates when pan-TB TB regimen performs better and blue when SoC regimen performs better. B, diarylquinolines; BX, diarylquinoline- and novel drug X–containing regimen; CFR, case-fatality ratio; DST, drug susceptibility testing; R, rifamycins; re-treat, those with previously treated TB; SoC, standard of care; X, additional novel drug X.

Figure 4. Sensitivity analysis for TB treatment regimen comparison after use in multiple patient cohorts in study of potential of pan-TB treatment to drive emergence of novel resistance. Comparison shows an outcome of proportion of patients durably cured in the 10th cohort when using either the pan-TB or the SoC approach for 10 cohorts. A) Univariate sensitivity analysis, sampling parameter sets with 1 parameter fixed at an extreme of its 95% CI, where blue circles indicate high parameter values and red circles low parameter values. B) Multivariate sensitivity analysis varying 2 resistance-related parameters simultaneously, where red indicates when pan-TB TB regimen performs better and blue when SoC regimen performs better. B, diarylquinolines; BX, diarylquinoline- and novel drug X–containing regimen; CFR, case-fatality ratio; DST, drug susceptibility testing; R, rifamycins; re-treat, those with previously treated TB; SoC, standard of care; X, additional novel drug X.

Main Article

Page created: June 21, 2024
Page updated: July 20, 2024
Page reviewed: July 20, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external